The goal of the Protocol Review and Monitoring System (PRMS) is to provide scientific oversight of cancer clinical trials conducted at City of Hope Comprehensive Cancer Center independent of the protection of human subjects afforded through the COM Institutional Review Board (IRB). This function is organized around the Cancer Center's Cancer Protocol Review and Monitoring Committee (CPRMC). City of Hope supports an internal Cancer Protocol Review and Monitoring Committee (CPRMC) to: 1) maintain the high quality of institutional clinical research;2) prioritize clinical research conducted by Cancer Center members; 3) provide a pathway for innovative clinical protocol research in the diagnosis, therapy, prevention and control of cancer to gain full access to shared resources and services supported by the Cancer Center Support Grant (CCSG). Scientific review requiring full committee vote is required for all new trials, amendments to on-going trials, and continuing trials?the latter on a yearly basis. The scientific review for new trials includes an evaluation of study design, scientific rationale, potential for accrual and biostatistical input for all new studies. Review of annual continuations includes an examination of actual accrual. Investigator-initiated Cancer Center-supported clinical protocols cannot have access to any of the Center's core facilities without full approval of the study by the CPRMC. Data and safety monitoring is conducted in compliance with the NCI-approved Data and Safety Monitoring Plan for Cancer Clinical Trials. This level of review provides an independent means of confirming the efficacy of the investigational treatment programs ongoing in the Cancer Center. The total annual budget of the CPRMC is $125,483 of which the institution pays 52% and CCSG funding is requested for $ 60,819, or 48% of the total. Total staffing for the core is 2.99 FTEs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-27
Application #
8182274
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-12-01
Budget End
2010-11-30
Support Year
27
Fiscal Year
2010
Total Cost
$84,530
Indirect Cost
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Zhang, Bin; Nguyen, Le Xuan Truong; Li, Ling et al. (2018) Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Nat Med 24:450-462
Kirschbaum, Mark H; Frankel, Paul; Synold, Timothy W et al. (2018) A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study. Br J Haematol 180:445-448
Zhang, Keqiang; Wang, Jinhui; Yang, Lu et al. (2018) Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1? and APC2 gene expression in non-small cell lung cancer. Mol Cancer 17:153
Liu, Liang; Yang, Lin; Yan, Wei et al. (2018) Chemotherapy Induces Breast Cancer Stemness in Association with Dysregulated Monocytosis. Clin Cancer Res 24:2370-2382
Woyach, Jennifer A; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med 379:2517-2528
Moreira, Dayson; Adamus, Tomasz; Zhao, Xingli et al. (2018) STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers. Clin Cancer Res 24:5948-5962
Choi, Audrey H; O'Leary, Michael P; Chaurasiya, Shyambabu et al. (2018) Novel chimeric parapoxvirus CF189 as an oncolytic immunotherapy in triple-negative breast cancer. Surgery 163:336-342
Golfetto, Ottavia; Wakefield, Devin L; Cacao, Eliedonna E et al. (2018) A Platform To Enhance Quantitative Single Molecule Localization Microscopy. J Am Chem Soc 140:12785-12797
Wolfson, Julie A; Richman, Joshua S; Sun, Can-Lan et al. (2018) Causes of Inferior Outcome in Adolescents and Young Adults with Acute Lymphoblastic Leukemia: Across Oncology Services and Regardless of Clinical Trial Enrollment. Cancer Epidemiol Biomarkers Prev 27:1133-1141
Wood, Kevin; Byron, Elizabeth; Janisch, Linda et al. (2018) Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol 41:963-966

Showing the most recent 10 out of 1396 publications